Histone deacetylase inhibitors in multiple myeloma
Mené sur 637 patients atteints d'un myélome multiple récidivant ou réfractaire, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de vorinostat à un traitement par bortezomib
A hallmark of many tumours is increased deacetylation of histone and non-histone proteins due to an increase in activity of histone deacetylase (HDAC). Various cellular processes are adversely affected by increased histone deacetylation promoting transcriptional suppression and also by deacetylation changing the functions of numerous non-histone proteins. The cellular processes affected include pathways central to cancer pathogenesis such as apoptosis, cell-cycle regulation and differentiation, ...
The Lancet Oncology , commentaire, 2012